Arjan Diepstra
dr.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Latest publications
(215)
Activities
(38)
Press/Media
(6)
Prizes
(4)
Datasets
(1)
Supervised work
(11)
Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
Published in: International Journal of Molecular Sciences
Access to document
10.3390/ijms232213751
document
The treatment of young patients with Hodgkin lymphoma (HL) is often successful but a significant proportion of patients suffers from late toxicity. In the current era there are new opportunities for less toxic and more targeted treatment options. In this respect, the anti-apoptotic pathway is an attractive target since Hodgkin tumor cells abundantly express components of this pathway. We measured the effect of BH3 mimetics that interfere with anti-apoptotic proteins in cell lines, also in combination with the standard of care chemotherapeutic doxorubicin and the recently discovered preclinically...
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma: a population-based analysis
Published in: European Journal of Cancer
Access to document
10.1016/j.ejca.2022.09.008
document
Background: Patients with angioimmunoblastic T-cell lymphoma (AITL) are treated with cyclophosphamide, doxorubicin, vincristine and prednisone with or without etoposide (CHO(E)P). In the majority of cases, Epstein–Barr virus (EBV)-positive B-cells are present in the tumour. There is paucity of research examining the effect of rituximab when added to CHO(E)P. In this nationwide, population-based study, we analysed the impact of rituximab on overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) of patients with AITL. Methods: Patients with AITL diagnosed between 2014 and 2020 treated with ≥one cycle...
Frederik O. Meeuwes, Mirian Brink, Marjolein W.M. van der Poel, Marie José Kersten, Mariëlle Wondergem, Pim G.N.J. Mutsaers, Lara Böhmer, Sherida Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Arjan Diepstra, Tjeerd J.F. Snijders, Wouter J. Plattel, Gerwin A. Huls, Joost S.P. Vermaat, Marcel Nijland
Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica
Published in: Frontiers in Immunology
Access to document
10.3389/fimmu.2022.943574
document
Background: Although polymyalgia rheumatica (PMR) is a very common rheumatic inflammatory disease, current insight into the pathobiology of PMR is limited and largely based on studies in blood. We investigated T helper 1 (TH1) and T helper 17 (TH17) cell responses in blood, synovial fluid and bursa tissue of patients with PMR. Materials and methods: Blood samples were collected from 18 patients with new-onset PMR and 32 healthy controls. Synovial fluid was aspirated from the inflamed shoulder bursae or biceps tendon sheath of 13 patients. Ultrasound-guided biopsies of...
Rosanne D Reitsema, William F Jiemy, Lieske Wekema, Annemieke M H Boots, Peter Heeringa, Minke G Huitema, Wayel H Abdulahad, Yannick van Sleen, Maria Sandovici, Caroline Roozendaal, Arjan Diepstra, Thomas Kwee, Bhaskar Dasgupta, Elisabeth Brouwer, Kornelis S M van der Geest
Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals
Published in: Blood Advances
Access to document
10.1182/bloodadvances.2021006755
document
Monocytosis may occur in numerous inflammatory conditions but is also the defining feature of chronic myelomonocytic leukemia (CMML). Clonal somatic mutations detectable in CMML may occur with ageing in otherwise healthy individuals, so-called “clonal hematopoiesis” (CH). We investigated whether the combination of CH and monocytosis would represent an early developmental stage of CMML. We studied community-dwelling individuals with monocytosis (≥ 1 x 109/L and ≥10% of leukocytes) in the population-based Lifelines cohort (n=144676 adults). The prevalence and spectrum of CH were evaluated for individuals ≥60 years with monocytosis...
Isabelle A van Zeventer, Aniek O de Graaf, Theresia N Koorenhof-Scheele, Bert A van der Reijden, Melanie van der Klauw, Avinash G Dinmohamed, Arjan Diepstra, Jan Jacob Schuringa, Luca Malcovati, Gerwin Huls, Joop H Jansen